Research programme: LOX inhibitors - Pharmaxis

Drug Profile

Research programme: LOX inhibitors - Pharmaxis

Alternative Names: LOX; LOXL2

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator Pharmaxis
  • Developer Pharmaxis; Synairgen
  • Class Pyrans; Small molecules
  • Mechanism of Action LOXL2 protein-inhibitors; Protein-lysine 6-oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Hepatic fibrosis; Pulmonary fibrosis; Renal fibrosis
  • Research Non-alcoholic steatohepatitis

Most Recent Events

  • 10 Mar 2017 Pharmacodynamics data from a preclinical trial in Pulmonary fibrosis released by Synairgen
  • 10 Mar 2017 Synairgen in collaboration with Pharmaxis plans a phase I trial of a LOXL2 inhibitor for Pulmonary fibrosis in the second half 2017
  • 16 Sep 2015 Early research in Non-alcoholic steatohepatitis in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top